Compare Danaher Corporation (DHR) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Nasdaq Inc — how do they compare? Danaher Corporation trades at $219.83 (market cap $152.87B), while Nasdaq Inc trades at $93.58 (market cap $51.63B). The key difference: Danaher Corporation is far larger — about 3× Nasdaq Inc's market cap, and Nasdaq Inc pays the higher dividend (1.26%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Nasdaq Inc for 126 Days on average.
| DHR | NDAQ | |
|---|---|---|
Market Cap | $152.87B | $51.63B |
Volume | 5,228,698 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $242.05 | $100.98 |
52-Week Low | $161.91 | $76.85 |
Typical Hold Time | 69 Days | 126 Days |
Enterprise Value | $175.08B | $58.09B |
Dividend Yield | 0.74% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Nasdaq (NDAQ) trades at $93.51, up 1.72% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. Analyst consensus is a Buy with a $110.43 price target, supported by positive news on AI platform adoption and index changes.
Outlook remains positive given earnings momentum and Financial Technology growth, though risks include market volatility and debt levels. The stock offers upside to consensus targets but faces execution risks in tech integration and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
